Eduardo J. Schiffrin
EPFL Innovation Park
Lausanne, VD, Switzerland
Lausanne, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.
Journal: Rheumatology (Oxford, England)
Published: June 09, 2019
Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
Journal: Annals of the rheumatic diseases
Published: September 27, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Journal: Annals of the rheumatic diseases
Published: October 27, 2017
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.
Journal: The Journal of allergy and clinical immunology
Published: May 19, 2016
Elevated serum levels of free interleukin-18 in adult-onset Still's disease.
Journal: Rheumatology (Oxford, England)
Published: November 20, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026